Back HCV Treatment

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy

Older age is associated with a lower likelihood of sustained response to pegylated interferon plus ribavirin in genotype 3 chronic hepatitis C patients, and people 50 years or older may benefit from longer treatment, according to a study presented at the recent Digestive Disease Week annual meeting (DDW 2009) in Chicago.

Read more: